What question did this study set out to answer?

To assess the real-world effectiveness of sutimlimab in patients with cold agglutinin disease.

December 8, 2025BloodOpen Access

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

View Full Paper

Ask AI

Bookmark

Authors

CVCarlo ViscoUniversity of Verona MKMoritz KleemissUniversity of Bonn JCJoan CidCanary Institute of Cancer Research

Discussion

Member takes

Implication

International evaluation shows sutimlimab improves anemia and reduces complications in cold agglutinin disease patients, suggesting efficacy of treatment.

Key Points

To assess the real-world effectiveness of sutimlimab in patients with cold agglutinin disease.
Evaluated 54 patients treated with sutimlimab in several countries.
Collected data on medical history, treatments, laboratory parameters at different time points.
Patients classified based on hemoglobin response after treatment.
Sutimlimab significantly increased hemoglobin levels over time.
Overall response rates reached 86% at various follow-up points.
Many patients became transfusion-independent, with low incidence of severe complications.

Cite This Study

Visco et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0b6 https://doi.org/10.1182/blood-2025-1100

View Full Paper

Ask AI

Bookmark

Implication

International evaluation shows sutimlimab improves anemia and reduces complications in cold agglutinin disease patients, suggesting efficacy of treatment.

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Discussion

Member takes

Implication

Key Points

Cite This Study

Real world use of sutimlimab in patients with cold agglutinin disease: An international study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider